We asked John for three reasons why the future is bright for life sciences in New Jersey:
1. Talent: New Jersey is the talent mecca for life sciences with expertise throughout the product lifecycle, particularly in product commercialization: Forty percent of all FDA approvals in 2014 were from companies with a footprint in the state.
2. Location, location, location: Fourteen of the top 20 pharmaceutical companies call New Jersey home. New Jersey is also home to leading academic institutions, prime real estate at reasonable costs, five convenient airports with nonstop flights to anywhere in the world, and a train ride away from New York and Washington, D.C.
3. Unparalleled support: At the forefront of support for a vibrant and fertile life science ecosystem is BioNJ, a powerful network of 400 member companies representing research-based life sciences companies and stakeholders. BioNJ also acts as a clearinghouse for the myriad of support resources for New Jersey life science startups while working closely with the N.J. EDA.
John F. Kouten has more than 20 years of experience in life science. He now heads JFK Communications, a firm dedicated to providing innovative communication solutions for the life sciences industry.